Skip to main content
. Author manuscript; available in PMC: 2022 Nov 4.
Published in final edited form as: Ann Surg. 2019 Sep;270(3):400–413. doi: 10.1097/SLA.0000000000003468

FIGURE 3.

FIGURE 3.

Median overall survival (OS) was 32 months (95% CI, 25.2–38.6). A, No significant OS difference was found between FLX and GNP. B, Patients who received ≥7 cycles of FLX had superior survival than those with <7 cycles. C, Patients with >50% decline of CA 19–9 level after neoadjuvant chemotherapy had significantly superior OS than those with CA 19–9 decline <50%. D, Patients with pCR and pPR had improved OS compared with pLR patients.